Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Steve Knapper

Showing results (11-20 of 14) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 14 results.
American Journal of Hematology|November 23, 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromesAndrew M Brunner, Jordi Esteve, Kimmo Porkka, et al.
Cancer Cell|January 22, 2011
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemiaNicolas Goardon, Emanuele Marchi, Ann Atzberger, et al.
British Journal of Haematology|June 12, 2023
Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromesJustin Loke, Vinit Upasani, Charlotte Gaskell, et al.
British Journal of Haematology|May 3, 2026
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United KingdomAlexandros Rampotas, Gabriel Naylor-Layland, Clare Brown, et al.
Pageof 2

Showing results (11-20 of 14) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 14 results.
American Journal of Hematology|November 23, 2023
Phase Ib study of sabatolimab (MBG453), a novel immunotherapy targeting TIM-3 antibody, in combination with decitabine or azacitidine in high- or very high-risk myelodysplastic syndromesAndrew M Brunner, Jordi Esteve, Kimmo Porkka, et al.
Cancer Cell|January 22, 2011
Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemiaNicolas Goardon, Emanuele Marchi, Ann Atzberger, et al.
British Journal of Haematology|June 12, 2023
Defective T-cell response to COVID-19 vaccination in acute myeloid leukaemia and myelodysplastic syndromesJustin Loke, Vinit Upasani, Charlotte Gaskell, et al.
British Journal of Haematology|May 3, 2026
Real-world treatment patterns and outcomes in accelerated and blast-phase myeloproliferative neoplasms: Insights from a large multi-centre cohort analysis in the United KingdomAlexandros Rampotas, Gabriel Naylor-Layland, Clare Brown, et al.
Pageof 2